CN1976930B - 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮 - Google Patents

用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮 Download PDF

Info

Publication number
CN1976930B
CN1976930B CN2005800151994A CN200580015199A CN1976930B CN 1976930 B CN1976930 B CN 1976930B CN 2005800151994 A CN2005800151994 A CN 2005800151994A CN 200580015199 A CN200580015199 A CN 200580015199A CN 1976930 B CN1976930 B CN 1976930B
Authority
CN
China
Prior art keywords
alkyl
group
compound
carbonyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800151994A
Other languages
English (en)
Chinese (zh)
Other versions
CN1976930A (zh
Inventor
B·R·R·克斯特莱恩
S·M·H·温德维勒
N·M·F·金德曼斯
D·L·N·G·苏勒罗克斯
P·J·-M·B·拉博伊森
P·T·B·P·威格林克
A·A·皮特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Infectious Diseases Diagnostics BVBA
Janssen R&D Ireland ULC
Original Assignee
Tibotec BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec BVBA filed Critical Tibotec BVBA
Publication of CN1976930A publication Critical patent/CN1976930A/zh
Application granted granted Critical
Publication of CN1976930B publication Critical patent/CN1976930B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2005800151994A 2004-05-17 2005-05-17 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮 Expired - Fee Related CN1976930B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04102170 2004-05-17
EP04102170.0 2004-05-17
PCT/EP2005/052263 WO2005111035A1 (en) 2004-05-17 2005-05-17 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents

Publications (2)

Publication Number Publication Date
CN1976930A CN1976930A (zh) 2007-06-06
CN1976930B true CN1976930B (zh) 2011-01-19

Family

ID=34929105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800151994A Expired - Fee Related CN1976930B (zh) 2004-05-17 2005-05-17 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮

Country Status (14)

Country Link
US (2) US7622581B2 (pl)
EP (1) EP1751156B1 (pl)
JP (1) JP2007538050A (pl)
CN (1) CN1976930B (pl)
AR (1) AR049637A1 (pl)
AT (1) ATE481403T1 (pl)
BR (1) BRPI0511173A (pl)
DE (1) DE602005023600D1 (pl)
ES (1) ES2351702T3 (pl)
MX (1) MXPA06013313A (pl)
PL (1) PL1751156T3 (pl)
RU (1) RU2377243C2 (pl)
TW (1) TW200607502A (pl)
WO (1) WO2005111035A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113290A1 (en) 2006-04-03 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
WO2008037783A1 (en) * 2006-09-29 2008-04-03 Tibotec Pharmaceuticals Ltd. Process for preparing 2-oxo-2,5-dihydro-1h-pyrido[3,2-b]indole-3-carbonitriles
EP2417140B1 (en) 2009-04-09 2014-11-26 Boehringer Ingelheim International GmbH Inhibitors of hiv replication
US20130060047A1 (en) * 2010-05-14 2013-03-07 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2464042C1 (ru) * 2011-03-31 2012-10-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
SG11201400555SA (en) 2011-09-16 2014-04-28 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
RU2640081C1 (ru) * 2016-07-11 2017-12-26 Общество с ограниченной ответственностью "ЛАЙФ САЙНСЕС ОХФК" Фармацевтическая композиция и лекарственное средство на основе клатратного комплекса N-карбамоилметил-4-фенил-2-пирролидон или 4-фенилпирацетам с циклодекстрином, способы его получения (варианты)
WO2019180369A1 (fr) * 2018-03-20 2019-09-26 Compagnie Generale Des Etablissements Michelin Câblé textile aramide perfectionne à au moins triple torsion
CN108530381B (zh) * 2018-05-07 2021-09-21 上海科技大学 一种由酰胺酯制备二胺衍生物的方法
US20240208984A1 (en) * 2021-03-31 2024-06-27 Virginia Commonwealth University Bivalent ligands to understand dimerization of the mu opioid receptor and the chemokine receptor ccr5 in neurological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
PL175564B1 (pl) 1993-10-01 1999-01-29 Astra Ab Sposób i urządzenie do formowania leku w proszku oraz lek w proszku
CN1165291C (zh) 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
ES2201485T3 (es) 1997-03-26 2004-03-16 Janssen Pharmaceutica N.V. Palets que tienen un nucleo recubierto con un agente antifungico y un polimero.
US20020182151A1 (en) * 2000-12-18 2002-12-05 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Benzoylalkylindolepyridinium componds and pharmaceutical compositions comprising such compounds
WO2002059123A2 (en) 2000-12-18 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
EP1438310B1 (en) 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors
BR0316209A (pt) * 2002-11-15 2005-09-27 Tibotec Pharm Ltd Indolpiridìnio substituìdo como compostos antiinfecciosos

Also Published As

Publication number Publication date
RU2006144852A (ru) 2008-06-27
JP2007538050A (ja) 2007-12-27
CN1976930A (zh) 2007-06-06
MXPA06013313A (es) 2007-02-02
EP1751156B1 (en) 2010-09-15
EP1751156A1 (en) 2007-02-14
WO2005111035A1 (en) 2005-11-24
TW200607502A (en) 2006-03-01
PL1751156T3 (pl) 2011-03-31
DE602005023600D1 (de) 2010-10-28
US20070167434A1 (en) 2007-07-19
ES2351702T3 (es) 2011-02-09
AR049637A1 (es) 2006-08-23
BRPI0511173A (pt) 2007-12-04
ATE481403T1 (de) 2010-10-15
US20100029635A1 (en) 2010-02-04
RU2377243C2 (ru) 2009-12-27
US7622581B2 (en) 2009-11-24

Similar Documents

Publication Publication Date Title
CN1976930B (zh) 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮
CN1953982B (zh) 4-取代-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
CN100457754C (zh) 作为抗感染化合物的取代的吲哚吡啶
CN1953983B (zh) 1-杂环基-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
CN1953978B (zh) 作为抗病毒剂的5-取代的1-苯基-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮及其类似物
CN100491360C (zh) 广谱2-(取代的-氨基)-苯并唑磺酰胺hiv蛋白酶抑制剂
CN100582097C (zh) 取代的苯并异噁唑磺酰胺广谱hiv蛋白酶抑制剂
CN106632424A (zh) 以1‑(2‑吡啶)‑9‑苄基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN101935303B (zh) 广谱取代的苯并咪唑磺酰胺hiv蛋白酶抑制剂
CN106632420A (zh) 以1‑(2‑吡啶)‑9‑丁基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN104774241A (zh) 含吲哚骨架的二氢吡唑磺胺甾体皂苷苷元衍生物、其制备方法及应用
CN106632418A (zh) 以1‑(2‑吡啶)‑9‑辛基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN106478680A (zh) 1‑(2‑吡啶)‑9‑环丙基甲基‑β‑咔啉的氯化铜配合物及其合成方法和应用
CN106432287A (zh) 1‑(2‑吡啶)‑9‑(2‑乙氧基乙基)‑β‑咔啉的硝酸铜配合物及合成方法和应用
ZA200503835B (en) Substituted indolepyridinium as anti-infective compounds
CN106632414A (zh) 1‑(2‑吡啶)‑9‑(2‑乙氧基乙基)‑β‑咔啉的氯化铜配合物及合成方法和应用
CN106478679A (zh) 1‑(2‑吡啶)‑9‑环丙基甲基‑β‑咔啉的硝酸铜配合物及其合成方法和应用
CN106478684A (zh) 以1‑(2‑吡啶)‑9‑庚基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN106632417A (zh) 以1‑(2‑吡啶)‑9‑壬基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN106478689A (zh) 1‑(2‑吡啶)‑9‑(4‑甲基苄基)‑β‑咔啉的氯化铜配合物及其合成方法和应用
CN106478678A (zh) 1‑(2‑吡啶)‑9‑(萘‑2‑甲基)‑β‑咔啉的硝酸铜配合物及其合成方法和应用
CN106432289A (zh) 以1‑(2‑吡啶)‑9‑戊基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN106478682A (zh) 1‑(2‑吡啶)‑9‑(4‑氟苄基)‑β‑咔啉的氯化铜配合物及其合成方法和应用
CN106632416A (zh) 以1‑(2‑吡啶)‑9‑异戊基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN104829684A (zh) 含吲哚骨架的二氢吡唑氧肟酸甾体皂苷苷元衍生物、其制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110119

Termination date: 20120517